CY2531B1 - Guanine derivative - Google Patents

Guanine derivative

Info

Publication number
CY2531B1
CY2531B1 CY0500061A CY0500061A CY2531B1 CY 2531 B1 CY2531 B1 CY 2531B1 CY 0500061 A CY0500061 A CY 0500061A CY 0500061 A CY0500061 A CY 0500061A CY 2531 B1 CY2531 B1 CY 2531B1
Authority
CY
Cyprus
Prior art keywords
guanine derivative
guanine
derivative
Prior art date
Application number
CY0500061A
Other languages
English (en)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2531(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of CY2531B1 publication Critical patent/CY2531B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0500061A 1995-01-20 2005-11-16 Guanine derivative CY2531B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
CY2531B1 true CY2531B1 (en) 2006-04-12

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500061A CY2531B1 (en) 1995-01-20 2005-11-16 Guanine derivative

Country Status (40)

Country Link
US (1) US6107302A (da)
EP (1) EP0804436B1 (da)
JP (1) JP3176633B2 (da)
KR (1) KR100376074B1 (da)
CN (1) CN1049893C (da)
AP (1) AP662A (da)
AR (1) AR002270A1 (da)
AT (1) ATE302777T1 (da)
AU (1) AU702794B2 (da)
BG (1) BG63393B1 (da)
BR (1) BR9606768A (da)
CA (1) CA2210799C (da)
CY (1) CY2531B1 (da)
CZ (1) CZ297065B6 (da)
DE (1) DE69635106T2 (da)
DK (1) DK0804436T3 (da)
EA (1) EA000364B1 (da)
EE (1) EE03528B1 (da)
ES (1) ES2248806T3 (da)
FI (1) FI973063A (da)
GB (1) GB9501178D0 (da)
GE (1) GEP20001940B (da)
HR (1) HRP960024B1 (da)
HU (1) HU222993B1 (da)
IL (1) IL116831A (da)
IN (1) IN182468B (da)
IS (1) IS2268B (da)
NO (1) NO315558B1 (da)
NZ (1) NZ298851A (da)
OA (1) OA10499A (da)
PL (1) PL182175B1 (da)
RO (1) RO118693B1 (da)
RS (1) RS49518B (da)
SI (1) SI0804436T1 (da)
SK (1) SK285329B6 (da)
TR (1) TR199700656T1 (da)
UA (1) UA46001C2 (da)
UY (1) UY25779A1 (da)
WO (1) WO1996022291A1 (da)
ZA (1) ZA96449B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
DK0874631T3 (da) * 1996-01-19 2004-03-22 Glaxo Group Ltd Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CN1250449A (zh) * 1997-01-17 2000-04-12 味之素株式会社 新型z－伐昔洛韦结晶
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
CN100408579C (zh) * 2001-02-24 2008-08-06 贝林格尔英格海姆法玛两合公司 黄嘌呤衍生物,其制法及其作为药物组合物的用途
EP1436295A4 (en) * 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006011874A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries, Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
IS2268B (is) 2007-07-15
KR100376074B1 (ko) 2003-06-02
EA000364B1 (ru) 1999-06-24
CA2210799A1 (en) 1996-07-25
SK285329B6 (sk) 2006-11-03
ZA96449B (en) 1996-08-07
NZ298851A (en) 1999-01-28
GEP20001940B (en) 2000-02-05
FI973063A (fi) 1997-09-18
HUP9801836A3 (en) 1999-06-28
BR9606768A (pt) 1997-12-30
FI973063A0 (fi) 1997-07-18
KR19980701525A (ko) 1998-05-15
IN182468B (da) 1999-04-17
HRP960024A2 (en) 1997-10-31
CZ229497A3 (en) 1997-12-17
SI0804436T1 (sl) 2006-02-28
GB9501178D0 (en) 1995-03-08
DK0804436T3 (da) 2005-12-27
HU222993B1 (hu) 2004-01-28
OA10499A (en) 2002-04-10
ATE302777T1 (de) 2005-09-15
UA46001C2 (uk) 2002-05-15
YU3396A (sh) 1998-12-23
AP9701058A0 (en) 1997-10-31
AU4453996A (en) 1996-08-07
EA199700124A1 (ru) 1997-12-30
EE9700175A (et) 1998-02-16
CN1179159A (zh) 1998-04-15
UY25779A1 (es) 2000-08-21
JP3176633B2 (ja) 2001-06-18
AU702794B2 (en) 1999-03-04
PL182175B1 (pl) 2001-11-30
NO973326D0 (no) 1997-07-18
DE69635106T2 (de) 2006-06-08
RS49518B (sr) 2006-10-27
IS4527A (is) 1997-07-15
IL116831A (en) 1998-10-30
EP0804436B1 (en) 2005-08-24
NO973326L (no) 1997-09-16
TR199700656T1 (xx) 1998-03-21
US6107302A (en) 2000-08-22
ES2248806T3 (es) 2006-03-16
EP0804436A1 (en) 1997-11-05
PL321326A1 (en) 1997-12-08
WO1996022291A1 (en) 1996-07-25
HUP9801836A2 (hu) 1999-05-28
HRP960024B1 (en) 2005-08-31
AR002270A1 (es) 1998-03-11
RO118693B1 (ro) 2003-09-30
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
JPH11503718A (ja) 1999-03-30
SK96597A3 (en) 1998-02-04
DE69635106D1 (de) 2005-09-29
AP662A (en) 1998-08-19
CA2210799C (en) 2008-06-10
MX9705462A (es) 1997-10-31
CZ297065B6 (cs) 2006-08-16
IL116831A0 (en) 1996-05-14
BG101833A (en) 1998-04-30
EE03528B1 (et) 2001-10-15
NO315558B1 (no) 2003-09-22

Similar Documents

Publication Publication Date Title
CY2531B1 (en) Guanine derivative
GB9508565D0 (en) Quiazoline derivative
NZ305444A (en) 4-anilino-7-alkoxy-quinazoline derivatives
IL152383A0 (en) 5-amino-3-cyano-4-ethylsulfinyl-1- phenyl-pyrazole derivatives
IL135376A0 (en) Hydroxyalkyl-phenyl derivatives
GB2306473A8 (en) Glucoxide derivatives
ZA96228B (en) Indolepiperidine derivatives
ZA969278B (en) Purin-6-one derivatives
HU9600876D0 (en) Benzonitril- and -fluoride derivatives
HUP9600107A2 (en) 9-substituted-2-(2-n-alkoxy-phenyl)-purin-6-one derivatives
NZ332395A (en) Benzonthiazole derivatives
SI0758644T1 (en) Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives
SG60005A1 (en) 1-Fluorocyclohexene-difluorophenyl derivatives
HUP9900672A3 (en) Pyrroloazepine derivatives
IL123621A0 (en) Diarylalkenylamine derivatives
HK1003299A1 (en) Benzisothiazolyl-substituted aminomethylchroman derivatives
ZA964470B (en) Cycloalkane-benzylidene derivatives
IL117858A0 (en) 4-Indolypiperazinyl derivatives
GR3036572T3 (en) 4-amino-benzoylguanidine derivatives
HU9602324D0 (en) Piperidinyl-methyl-oxazolidinon derivatives
HK1011013A1 (en) Fluorobenzylether derivatives
GB9516349D0 (en) Aza-anthracyclinone derivatives
SI0725062T1 (en) 4-mercapto-benzoylguanidine derivatives
EP0804205A4 (en) 4-AZA-19-NORANDROSTANDERIVATE
HK1003055A1 (en) Guanine derivative